Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies (NOVIT1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04393363|
Recruitment Status : Active, not recruiting
First Posted : May 19, 2020
Last Update Posted : February 2, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Chemotherapy-induced Peripheral Neuropathy|
Haematological malignancies can be treated with chemotherapy if the patient tolerates the treatment. However, many patients develop complications during treatment including chemotherapy-induced peripheral neuropathy (CIPN) and/or impaired memory. Even though it is a well-known complication, no gold standard for CIPN assessment is known. Besides chemotherapy reduction or cessation, there is so far no sufficient prevention or treatment, therefore early detection and intervention is crucial.
The main purpose of this study is to find a reliable test for chemotherapy-induced peripheral neuropathy (CIPN) in order to predict early signs of CIPN. All included patients has to be scheduled for treatment with vincristine, bortezomib or lenalidomide regardless of haematological malignancy. Neuropathy and cognitive impairment will be tested at baseline (prior to treatment with chemotherapy), before each treatment course, 1 month after treatment and finally 1 year after onset of chemotherapy. CIPN will be examined by different methods: Clinician-based assessment, objective neurophysiological parameters and patient-reported outcome. A novel test using Perception Threshold Tracking (PTT), developed at Aalborg University, is included in the study. The test investigates the nerve excitability in both large and small fiber nerve fibers using two different electrodes. Blood samples will be collected, stored, and analyzed for deficiencies correlated to neuropathy.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Early Detection and Prevention of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies (the NOVIT Study)|
|Actual Study Start Date :||August 14, 2020|
|Estimated Primary Completion Date :||June 30, 2023|
|Estimated Study Completion Date :||December 31, 2030|
- Change in neuropathy assessed by change in the neurotoxicity (ntx)-subscale of the FACT/GOG-Ntx-13-Score [ Time Frame: 0-12 months ]A patient questionnaire with focus on Quality of Life and neuropathy. Range 0-52 with higher score meaning better Quality of Life (less neuropathy). Neuropathy will be defined as a 10 % reduction in the Ntx-score
- Change in nerve excitability assessed by Perception Threshold Tracking [ Time Frame: 0-12 months ]Assessment of nerve excitability in both large and small fiber nerves measured by two different electrodes.
- Change in The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) [ Time Frame: 0-12 months ]A grading scale 1-5 (with 5 as the worst) for neuropathy evaluated by the medical doctor based on the patients' symptoms.
- Change in the Total Neuropathy Score-Clinical [ Time Frame: 0-12 months ]A score based on clinical evaluation (pin and vibration sensibility, strength and reflexes) and subjective reports from the patient (sensory, motor and autonomic symptoms). The score grades from 0-28 with 28 at worst.
- Change in Quality of Life (The total FACT/GOG-Ntx-score) [ Time Frame: 0-12 months ]A patient questionnaire with focus on Quality of Life and neuropathy. This part will focus on Quality of Life. Score range from 0-160 with higher score meaning higher Quality of Life
- Change in Montreal Cognitive Assessment (MoCA) [ Time Frame: 0-12 months ]A quick and easy method to assess mild cognitive disturbance based on following parameters: Awareness, concentration, executive function, memory, abstract thinking, calculating abilities and orientation. The score is 0-30, score > 26 is normal (without cognitive disturbance).
- Change in the score for FACT/GOG-cog [ Time Frame: 0-12 months ]A patient questionnaire used to assess cognitive function. The score is measured from 0-132 with higher score meaning better Quality of Life
- Change in VagusTM Test [ Time Frame: 0-12 months ]A measurement for autonomic neuropathy by evaluation of heart rate in different positions
- Change in Bioimpendance [ Time Frame: 0-12 months ]Measurement of body composition in order to investigate loss of muscle mass, which can influence motor function and imitate or mask motor neuropathy
- Change in vitamin B12-level in blood test [ Time Frame: 0-12 months ]Measurement of deficiency/functional deficiency
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Men and women, age ≥ 18 years
- Scheduled for treatment with Vincristine (R-CHOP, CHOP, R-CHOEP, CHOEP, R-CVP, CVP or simi-lar), Bortezomib (VCD, MPV, VRD or similar) or Lenalidomide (VRD, len-dex or similar) regardless of type of haematological malignancy
- Not started chemotherapy treatment before enrollment (pretreatment with steroids is allowed)
- Associated to Department of Haematology, Aalborg University Hospital during the project period
- Signed informed consent form
- Able to read and speak Danish
- Known vitamin B12 deficiency and treated with either oral or intramuscular vitamin B12 within the last year
- Known neural damage or disease in the neural system (e.g. MS, Guillain-Barre etc.)
- Known severe skin disease
- Pregnancy or breastfeeding
- Inability to understand or comply with instructions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04393363
|Department of Haematology, Aalborg University Hospital|
|Aalborg, Denmark, 9000|
|Principal Investigator:||Marianne T Severinsen, MD, PhD||Aalborg University Hospital|
|Responsible Party:||Marianne Tang Severinsen, Consultant, Head of Research, Ass. Professor, Aalborg University Hospital|
|Other Study ID Numbers:||
|First Posted:||May 19, 2020 Key Record Dates|
|Last Update Posted:||February 2, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Assessment of nerve fiber excitability
Peripheral Nervous System Diseases
Nervous System Diseases
Neoplasms by Site